期刊
MULTIPLE SCLEROSIS AND RELATED DISORDERS
卷 22, 期 -, 页码 38-40出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.msard.2018.02.031
关键词
Multiple sclerosis; Autoimmune diseases
资金
- Biogen Idec
- Merck
- Genzyme
- Novartis
- Biogen
- Teva
- Biogen Novartis
Several reports indicate increased disease activity in patients with multiple sclerosis (MS) undergoing assisted reproductive techniques (ART), in the form of gonadtopin releasing hormone (GnRH) agonists. Other forms of ART treatments, like gonadotropin-treatment, have therefore been considered a safer option for MS-patients. We present a patient who despite being completely clinically and radiologically stable for eight years during disease modifying therapy experienced a nearly fulminant disease course almost immediately after starting gonadotropin- treatment, indicating that this form of follicle stimulating treatment could also be a major risk factor for MS disease activity.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据